GlassScriptPhysician profile
Catherine Miller
NPI 1013677442
$8,464.66
in general payments reported to CMS, 2019-2025
44 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,613 · 2023: $2,343 · 2024: $2,201 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,757 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,756.72 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,708.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,060.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $898.49 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $480.12 | 2023-2025 | Sunosi, Auvelity |
| Lilly USA, LLC | $434.92 | 2022-2025 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $316.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.86 | 2023-2025 | Jardiance |
| Corium, LLC | $260.94 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $234.85 | 2024-2025 | Qelbree, Tlando, Xyosted |
| Teva Pharmaceuticals USA, INC. | $228.21 | 2022-2023 | Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $219.89 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.99 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $185.09 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $179.42 | 2023-2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $165.42 | 2023-2024 | Jornay Pm |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $158.52 | 2022-2024 | Rexulti, Vyepti |
| Idorsia Pharmaceuticals US INC | $130.50 | 2022-2025 | Quviviq, Quviviq |
| Antares Pharma, INC. | $127.06 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $114.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $106.40 | 2022-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $96.55 | 2022-2023 | Belsomra, Steglatro, Verquvo |
| Amgen INC. | $95.44 | 2024-2025 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $73.45 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $63.99 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $63.99 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $58.45 | 2022-2025 | Livalo, Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.71 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $54.65 | 2022 | |
| Tolmar, INC. | $50.57 | 2023-2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $45.68 | 2024 | Tlando |
| Paratek Pharmaceuticals, INC. | $33.65 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $32.36 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $30.50 | 2022-2023 | Camzyos |
| Dexcom, INC. | $23.17 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $22.71 | 2025 | Inspire |
| Noven Therapeutics, LLC | $22.68 | 2024 | Xelstrym |
| Seqirus USA INC | $22.05 | 2025 | Flucelvax, Fluad |
| Amarin Pharma, INC. | $20.64 | 2022 | |
| Tris Pharma INC | $20.41 | 2025 | Dyanavel Xr |
| Ars Pharmaceuticals Operations, INC. | $20.33 | 2025 | Neffy |
| Athena Bioscience, LLC | $16.50 | 2024 | Qdolo |
| Medicure Pharma INC. | $15.83 | 2023 | Zypitamag |
| Azurity Pharmaceuticals, INC. | $15.19 | 2025 | Edarbyclor |
| Halozyme INC | $13.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.